Rolf A. Stahel

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

Medicine, Oncology, Chemotherapy +11

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Ken A. Olaussen, Ariane Dunant, Pierre Fouret et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

Medicine, Molecular Biology, Oncology +16

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper et al. · The Lancet Oncology · 2011 · 811 citations

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud et al. · The Lancet Oncology · 2022 · 744 citations

Medicine, Oncology, Pharmacology +16

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

Arnaud Scherpereel, Philippe Astoul, Thierry Berghmans et al. · European Respiratory Journal · 2009 · 636 citations · Full text

Medicine, Oncology, Surgery +17